U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Henkel in Advanced Talks to Acquire Olaplex at $2 Per Share 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
